Floreani, Annarosa

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 1,131

Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis

Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 533

Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study

Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 498

Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy

Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 441

Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis

Liu, X., Invernizzi, P., Lu, Y., Kosoy, R., Lu, Y., Bianchi, I., Podda, M., Xu, C., Xie, G., Macciardi, F., et al. (2010) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 398

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

The UK-PSCSC Consortium, Liu, J. Z., The International IBD Genetics Consortium, The International PSC Study Group, Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., Andreassen, O. A., et al. (2013) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 391

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

The UK-PSC Consortium, Ji, S.-G., The International IBD Genetics Consortium, The International PSC Study Group, Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., Kumasaka, N., et al. (2017) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 357

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

Harms, M. H., van Buuren, H. R., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Hirschfield, G. M., Parés, A., Floreani, A., Mayo, M. J., et al. (2019) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 289

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

Cordell, H. J., Han, Y., Mells, G. F., Li, Y., Hirschfield, G. M., Greene, C. S., Xie, G., Juran, B. D., Zhu, D., Qian, D. C., et al. (2015) · Nature Communications

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 287

Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome

Floreani, A., Rizzotto, E. R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L., & Baldo, V. (2005) · The American Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 230

Extrahepatic autoimmune conditions associated with primary biliary cirrhosis

Floreani, A., Franceschet, I., Cazzagon, N., Spinazzè, A., Buja, A., Furlan, P., Baldo, V., & Gershwin, M. E. (2015) · Clinical Reviews in Allergy & Immunology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 188

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

Murillo Perez, C. F., Harms, M. H., Lindor, K. D., van Buuren, H. R., Hirschfield, G. M., Corpechot, C., van der Meer, A. J., Feld, J. J., Gulamhusein, A., Lammers, W. J., et al. (2020) · American Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 188

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

Cordell, H. J., Fryett, J. J., Ueno, K., Darlay, R., Aiba, Y., Hitomi, Y., Kawashima, M., Nishida, N., Khor, S.-S., Gervais, O., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 182

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

Trivedi, P. J., Lammers, W. J., van Buuren, H. R., Parés, A., Floreani, A., Janssen, H. L. A., Invernizzi, P., Battezzati, P. M., Ponsioen, C. Y., Corpechot, C., et al. (2016) · Gut

Liver Diseases and ImmunityHepatocellular Carcinoma Treatment and Prognosis

Cited by 178

Environmental Basis of Autoimmunity

Floreani, A., Leung, P. S. C., & Gershwin, M. E. (2016) · Clinical Reviews in Allergy & Immunology

T-cell and B-cell ImmunologySystemic Lupus Erythematosus Research

Cited by 122

Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Comparative Analysis from Two Centers†

Cavazza, A., Caballería, L., Floreani, A., Farinati, F., Bruguera, M., Caroli, D., & Parés, A. (2009) · Hepatology

Liver Diseases and ImmunityHepatocellular Carcinoma Treatment and Prognosis

Cited by 114

Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

Murillo Perez, C. F., Fisher, H., Hiu, S., Kareithi, D., Adekunle, F., Mayne, T., Malecha, E., Ness, E., van der Meer, A. J., Lammers, W. J., et al. (2022) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 107

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 105

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

Corpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 94

Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history

Murillo Perez, C. F., Goet, J. C., Lammers, W. J., Gulamhusein, A., van Buuren, H. R., Ponsioen, C. Y., Carbone, M., Mason, A., Corpechot, C., Invernizzi, P., et al. (2018) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 88

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

D’Amato, D., De Vincentis, A., Malinverno, F., Viganò, M., Alvaro, D., Pompili, M., Picciotto, A., Palitti, V. P., Russello, M., Storato, S., et al. (2021) · JHEP Reports

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 85

Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis

Lemoinne, S., Cazzagon, N., El Mouhadi, S., Trivedi, P. J., Dohan, A., Kemgang, A., Ben Belkacem, K., Housset, C., Chretien, Y., Corpechot, C., et al. (2019) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 78

In vitro metabolic zonation through oxygen gradient on a chip

Tonon, F., Giobbe, G. G., Zambon, A., Luni, C., Gagliano, O., Floreani, A., Grassi, G., & Elvassore, N. (2019) · Scientific Reports

Liver physiology and pathology3D Printing in Biomedical Research

Cited by 76